ArcticZymes Technologies — M&A Activity 2022

Apr 19, 2022

ArcticZymes Technologies Signs New Supply Deal

Tromsø, April 19 2022 – ArcticZymes Technologies ASA (OSE: AZT) announces it has signed a new agreement with a large international Life Science company.

ArcticZymes Technologies has signed an original equipment manufacturing (OEM) agreement with a renowned and leading international Life Science company. The undisclosed partner will incorporate several of ArcticZymes´ enzymes into their extensive and synergistic portfolio. The partnership indirectly extends ArcticZymes´ commercial reach towards In Vitro Diagnostics (IVD) and bioprocessing development organizations. Such partnerships are integral to ArcticZymes´ commercial strategy to expand commercial presence and awareness throughout the industry via direct and indirect representation.

The partner is a global Life Science tools and solution provider with a workforce of more than 20,000 employees. ArcticZymes´ enzymes complement gaps in our partners portfolio to enable its customers with best-in-class technologies.

The agreement is a mutual starting point to build a long-term strategic partnership with the prospect to extend activities through other existing enzymes and new pipeline developments.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes is delighted to announce the new strategic partnership via this OEM agreement. We are proud to partner with leading Life Science companies to gain greater market relevance of our technologies."

For more information, please contact: ArcticZymes Technologies CEO, Jethro Holter CFO, Børge Sørvoll

Tel: +47 46 85 91 46 Tel: +47 95 29 01 87 ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.